title: Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients.
abstract: This study aims to evaluate the effects of an angiotensin receptor blocker (ARB)/calcium channel blocker combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation markers. We randomized 276 hypertensive patients to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing an olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following: body weight, systolic and diastolic blood pressure, fasting plasma glucose, fasting plasma insulin (FPI), M value, lipid profile, adiponectin (ADN), high sensitivity C-reactive protein (Hs-CRP), monocyte chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor-1β (MIP-1β). Olmesartan/amlodipine combination better reduced blood pressure, FPI, homeostasis model assessment index, and increased M value and ADN compared to olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly decreased Hs-CRP, MCP-1, and MIP-1β. In this multicenter, randomized, double-blind, clinical study, ARB/calcium antagonist combination resulted to be more effective than single monotherapies in reducing blood pressure, in improving insulin sensitivity, and in reducing inflammation parameters in patients with stage I essential hypertension.
authors.affiliation: Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, P.le C. Golgi 2, 27100, Pavia, Italy, giuseppe.derosa@unipv.it.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Derosa
authors.forename: Arrigo F G
authors.initials: AF
authors.lastname: Cicero
authors.forename: Anna
authors.initials: A
authors.lastname: Carbone
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Querci
authors.forename: Elena
authors.initials: E
authors.lastname: Fogari
authors.forename: Angela
authors.initials: A
authors.lastname: D'Angelo
authors.forename: Pamela
authors.initials: P
authors.lastname: Maffioli
mesh_terms: D017311:Amlodipine / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004338:Drug Combinations; D007093:Imidazoles; D008055:Lipids; D013777:Tetrazoles; D017311:Amlodipine; C437965:olmesartan
references.citation: Expert Opin Pharmacother. 2012 Jun;13(8):1091-9
references.pmid: 22515416
references.citation: Int J Obes (Lond). 2005 Mar;29 Suppl 1:S17-23
references.pmid: 15711577
references.citation: J Clin Invest. 1955 Sep;34(9):1345-53
references.pmid: 13252080
references.citation: Adv Ther. 2010 Jan;27(1):48-55
references.pmid: 20174905
references.citation: Hypertens Res. 2010 Aug;33(8):790-5
references.pmid: 20505674
references.citation: Circulation. 2001 Mar 6;103(9):1194-7
references.pmid: 11238260
references.citation: N Engl J Med. 1987 Aug 6;317(6):350-7
references.pmid: 3299096
references.citation: Postgrad Med. 2009 Mar;121(2):25-39
references.pmid: 19332960
references.citation: J Hum Hypertens. 2013 Jul;27(7):445-52
references.pmid: 23254596
references.citation: J Exp Med. 1993 Jun 1;177(6):1821-6
references.pmid: 7684437
references.citation: Diabetologia. 1972 Aug;8(4):260-6
references.pmid: 4673942
references.citation: Expert Opin Pharmacother. 2012 Apr;13(5):629-36
references.pmid: 22372508
references.citation: Trends Endocrinol Metab. 2002 Mar;13(2):84-9
references.pmid: 11854024
references.citation: Expert Opin Drug Saf. 2011 Sep;10(5):795-804
references.pmid: 21591999
references.citation: Am J Med. 2009 Mar;122(3):290-300
references.pmid: 19272490
references.citation: Nature. 1999 Apr 22;398(6729):718-23
references.pmid: 10227295
references.citation: Diabet Med. 1999 Sep;16(9):716-30
references.pmid: 10510947
references.citation: J Am Soc Hypertens. 2010 Jan-Feb;4(1):42-50
references.pmid: 20374950
references.citation: J Clin Chem Clin Biochem. 1977 Mar;15(3):121-30
references.pmid: 870610
references.citation: Expert Opin Pharmacother. 2011 Nov;12(16):2441-8
references.pmid: 21958068
references.citation: Clin Ther. 2008 Apr;30(4):587-604
references.pmid: 18498909
references.citation: Expert Opin Pharmacother. 2011 Jun;12(9):1351-8
references.pmid: 21510830
references.citation: J Hypertens. 2013 Mar;31 Suppl 1:S13-7
references.pmid: 23389083
references.citation: Eur J Gastroenterol Hepatol. 2012 Feb;24(2):164-71
references.pmid: 22081005
references.citation: Adv Ther. 2006 Sep-Oct;23(5):680-95
references.pmid: 17142202
references.citation: Intern Med. 2008;47(5):361-6
references.pmid: 18310964
references.citation: Drugs. 2007;67(9):1309-27
references.pmid: 17547473
references.citation: Circulation. 2010 Feb 23;121(7):e46-e215
references.pmid: 20019324
references.citation: Clin Chem. 1972 Jun;18(6):499-502
references.pmid: 4337382
references.citation: Nature. 1993 Jan 7;361(6407):79-82
references.pmid: 7678446
references.citation: Clin Exp Immunol. 1999 Jul;117(1):159-65
references.pmid: 10403930
references.citation: Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2186-91
references.pmid: 16990564
references.citation: Am J Physiol. 1979 Sep;237(3):E214-23
references.pmid: 382871
references.citation: Circ Res. 2004 Oct 29;95(9):858-66
references.pmid: 15514167
references.citation: Hypertens Res. 2008 Jan;31(1):43-50
references.pmid: 18360017
references.citation: Nat Med. 2001 Aug;7(8):947-53
references.pmid: 11479628
references.citation: J Am Soc Hypertens. 2010 Mar-Apr;4(2):90-8
references.pmid: 20400053
references.citation: Nat Med. 2001 Aug;7(8):941-6
references.pmid: 11479627
references.citation: Clin Chem. 1999 Dec;45(12):2136-41
references.pmid: 10585345
references.citation: Circulation. 2005 Oct 25;112(17):2735-52
references.pmid: 16157765
references.citation: Diabet Med. 2012 Jan;29(1):24-31
references.pmid: 21781149
references.citation: Clin Sci (Lond). 2006 Feb;110(2):143-52
references.pmid: 16411891
references.citation: Diabetologia. 1985 Jul;28(7):412-9
references.pmid: 3899825
references.citation: J Biol Regul Homeost Agents. 2012 Jan-Mar;26(1):67-79
references.pmid: 22475098
references.citation: Nat Med. 2002 Jul;8(7):731-7
references.pmid: 12068289